VIDEO: KEYNOTE-564 'critical trial' in kidney cancer
Click Here to Manage Email Alerts
Sumanta K. Pal, MD, co-director of Kidney Cancer Program at City of Hope, and a HemOnc Today Editorial Board Member, spoke with Healio about studies on renal cell carcinoma presented at the 2022 ASCO Genitourinary Cancers Symposium.
“Probably the biggest highlight in kidney cancer was the presentation of data by [Toni K. Choueiri, MD] related to KEYNOTE 564,” he said. “In my opinion, this was a really critical trial and, hopefully, sets the framework for future adjuvant studies that are going to report in the same space.”
The study assessed the use of adjuvant pembrolizumab (Keytruda, Merck) in patients with renal cell carcinoma.
He noted that the results, which were a follow-up of previously published findings from the study, were “similar if not better data supporting the use of adjuvant pembrolizumab in certain disease space, as we saw a hazard ratio that was essentially balanced with the initial presentation from 6 months ago.”
Pal added that, in the presentation of updated results from the trial, “there seemed to be more profound benefit in certain subpopulations of patients, like those with resected metastatic disease, and in particular those with high-risk disease or sarcomatoid features.”
Collapse
Healio Interview
Choueiri TK, et al. Abstract 290. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 17-19, 2022; San Francisco.
Read more about
Click Here to Manage Email Alerts